Boehringer's coagulation reversal agent Praxbind now also approved in EU

The European Commission has granted marketing authorization for Praxbind(idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery/urgent procedures or in situations of life-threatening or uncontrolled bleeding.

Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be granted a licence in the European Union, noted German family-owned pharma major Boehringer Ingelheim, the developer and marketer of both Praxbind and Pradaxa. Last month, the US Food and Drug Administration granted accelerated approval to Praxbind for use in patients who are taking Pradaxa during emergency situations (The Pharma Letter October 17).

“Leading the evolution of anticoagulation care”